Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma

Leukemia and Lymphoma

Volumn 53, Issue 7, 2012, Pages 1318-1320

  Touzeau, Cyrille ^a   Blin, Nicolas ^a   Clavert, Aline ^a   Roland, Virginie ^a   Loirat, Marion ^a   Tessoulin, Benoit ^a   Gouill, Steven Le ^a   Planche, Lucie ^a   Pennetier, Martine ^a   Mahe, Beatrice ^a   Mohty, Mohamad ^a   Malard, Florent ^a   Peterlin, Pierre ^a   Dubruille, Viviane ^a   Moreau, Philippe ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

elderly patient; Lenalidomide; multiple myeloma

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; INFECTION; KIDNEY FAILURE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; RECURRENCE; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84862639087     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.654116     Document Type: Article

References (10)

1. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. [Based on November 2010 SEER data submission, posted to the SEER website 2011.] Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975-2008/
2. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011;118:4519-4529.
3. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132. (Pubitemid 350146107)
4. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142. (Pubitemid 350146108)
5. Dimopoulos MA, Hussein M, Swern AS, et al. Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia 2011;25:1620-1626.
6. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473. (Pubitemid 44264086)
7. Lonial S, Knight RD, Dimopoulos M, et al. Effect of Len/Dex in MM in different age groups. Haematologica 2007;92(Suppl. 2): Abstract PO-663.
8. Quach H, Fernyhough L, Henderson R, et al. Lower-dose lenalidomide and dexamethasone reduces toxicity without compromising efficacy in patients with relapsed/refracory myeloma, who are aged ≥ 65 years or have renal impairment: planned interim results of a prospective multicentre phase II trial. Blood 2010;116(Suppl. 1): Abstract 1961.
9. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
10. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010;116:5838-5841.